Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30785244 | 0.81 | L3MBTL1 (0.31) | AKT1L3MBTL1 | |
| SCHEMBL27867642 | 0.79 | MEN1 (0.37) | AKT1ALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL17183930 | 0.79 | AKT1 (0.35) | AKT1ALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL29837226 | 0.77 | PAX8 (0.41) | AKT1ALDH1A1TSHRL3MBTL1PAX8 | |
| SCHEMBL29837166 | 0.75 | MT-CO2 (0.41) | AKT1TDP1L3MBTL1PAX8BCHE | |
| SCHEMBL29009658 | 0.72 | L3MBTL1 (0.38) | AKT1ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL29009665 | 0.71 | LMNA (0.38) | L3MBTL1 | |
| SCHEMBL29837260 | 0.71 | HDAC3 (0.36) | AKT1ALDH1A1L3MBTL1 | |
| SCHEMBL29837152 | 0.71 | MT-CO2 (0.39) | AKT1TDP1L3MBTL1PAX8BCHE | |
| SCHEMBL29805724 | 0.71 | MEN1 (0.37) | AKT1L3MBTL1PAX8BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10688081-B2 | Autotaxin inhibitor compounds | SABRE THERAPEUTICS LLC (US) | 2020-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10688081-B2 | Autotaxin inhibitor compounds | ENPP2, SERPINB1, SERPINE1 | AKT1 4070/4885ALDH1A1 4720/4885TSHR 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.